Carroll R, Benger J, Bramley K, Williams S, Griffin L, Potokar J, Gunnell D
School of Social and Community Medicine, University of Bristol, Bristol, UK.
Emergency Department, Bristol Royal Infirmary, Bristol, UK Faculty of Health and Life Sciences, University of the West of England, Bristol, UK.
Emerg Med J. 2015 Feb;32(2):155-60. doi: 10.1136/emermed-2013-202518. Epub 2013 Oct 7.
Paracetamol poisoning accounts for just under half of all self-poisoning cases that present to hospitals in England. Treatment with acetylcysteine is routine, yet recommendations regarding its use vary internationally and have recently been revised in England and Wales.
Data on all cases of paracetamol poisoning presenting to an adult inner city emergency department between May 2011 and April 2012 were prospectively collected using the Bristol Self-harm Surveillance Register.
Paracetamol overdoses accounted for 44% of adult self-poisoning cases. A quarter (26.9%) of patients required treatment with acetylcysteine and it was estimated that recent changes in treatment guidelines would increase that proportion to 32.6%. Paracetamol concentration was positively associated with the risk of any adverse reaction to acetylcysteine. 22.5% of patients experienced anaphylactoid reactions to acetylcysteine. There was no clear evidence of an association between risk of anaphylactoid reaction and blood paracetamol levels. Patients presenting with blood paracetamol levels greater than 200 mg/L at 4 h post-ingestion were at greater risk of repeat self-harm (HR 2.17, 95% CI 1.11 to 4.21, p=0.033).
The recent changes in UK treatment guidelines are expected to increase the proportion of our population requiring acetylcysteine by 5.7%. We found no clear evidence that risk of anaphylactoid or more general adverse reaction to acetylcysteine was increased in patients presenting with lower blood paracetamol concentrations. Blood paracetamol level was highlighted as a potentially useful clinical indicator for risk of repeat self-harm.
对乙酰氨基酚中毒占英国医院收治的所有自我中毒病例的近一半。使用乙酰半胱氨酸进行治疗是常规操作,但关于其使用的建议在国际上存在差异,并且最近在英格兰和威尔士进行了修订。
使用布里斯托尔自我伤害监测登记册前瞻性收集了2011年5月至2012年4月期间在市中心一家成人急诊科就诊的所有对乙酰氨基酚中毒病例的数据。
对乙酰氨基酚过量占成人自我中毒病例的44%。四分之一(26.9%)的患者需要使用乙酰半胱氨酸进行治疗,据估计,治疗指南的近期变化将使这一比例增加到32.6%。对乙酰氨基酚浓度与对乙酰半胱氨酸发生任何不良反应的风险呈正相关。22.5%的患者对乙酰半胱氨酸发生类过敏反应。没有明确证据表明类过敏反应风险与血液中对乙酰氨基酚水平之间存在关联。摄入后4小时血液中对乙酰氨基酚水平大于200mg/L的患者再次自我伤害的风险更高(风险比2.17,95%置信区间1.11至4.21,p=0.033)。
英国治疗指南的近期变化预计将使需要乙酰半胱氨酸治疗的人口比例增加5.7%。我们没有发现明确证据表明血液中对乙酰氨基酚浓度较低的患者对乙酰半胱氨酸发生类过敏反应或更普遍不良反应的风险增加。血液中对乙酰氨基酚水平被强调为再次自我伤害风险的一个潜在有用的临床指标。